Table 1 Baseline characteristics by treatment group.
R-CHOP (N = 56) | R2CHOP (N = 77) | Total (N = 133) | p-value | |
|---|---|---|---|---|
Age at incidence (years) | 0.018a | |||
Median | 70 | 63 | 66 | |
IQR | 57–75 | 54–72 | 56–73 | |
Range | 29–88 | 28–82 | 28–88 | |
Sex | 0.271b | |||
Male | 34 (60.7%) | 54 (70.1%) | 88 (66.2%) | |
Female | 22 (39.3%) | 23 (29.9%) | 45 (33.8%) | |
Ann Arbor stage | 0.172c | |||
2 | 12 (21.4%) | 10 (13.0%) | 22 (16.5%) | |
3 | 12 (21.4%) | 11 (14.3%) | 23 (17.3%) | |
4 | 32 (57.1%) | 56 (72.7%) | 88 (66.2%) | |
WHO performance score | 0.013c | |||
0 | 22 (41.5%) | 47 (61.0%) | 69 (53.1%) | |
1 | 16 (30.2%) | 24 (31.2%) | 40 (30.8%) | |
2 | 10 (18.9%) | 5 (6.5%) | 15 (11.5%) | |
3 | 5 (9.4%) | 1 (1.3%) | 6 (4.6%) | |
(Missing) | 3 | 0 | 3 | |
WHO PS (grouped) | 0.006c | |||
0 | 22 (41.5%) | 47 (61.0%) | 69 (53.1%) | |
1 | 16 (30.2%) | 24 (31.2%) | 40 (30.8%) | |
2 or 3 | 15 (28.3%) | 6 (7.8%) | 21 (16.2%) | |
(Missing) | 3 | 0 | 3 | |
LDH | 0.693b | |||
Within normal range | 16 (28.6%) | 19 (25.0%) | 35 (26.5%) | |
Elevated | 40 (71.4%) | 57 (75.0%) | 97 (73.5%) | |
(Missing) | 0 | 1 | 1 | |
Extra-nodal localizations | 0.300c | |||
None | 12 (21.4%) | 23 (29.9%) | 35 (26.3%) | |
1 | 22 (39.3%) | 21 (27.3%) | 43 (32.3%) | |
2 or more | 22 (39.3%) | 33 (42.9%) | 55 (41.4%) | |
IPI risk group | 0.013c | |||
Low | 12 (21.8%) | 9 (11.8%) | 21 (16.0%) | |
Low-intermediate | 8 (14.5%) | 22 (28.9%) | 30 (22.9%) | |
High-intermediate | 13 (23.6%) | 29 (38.2%) | 42 (32.1%) | |
High | 22 (40.0%) | 16 (21.1%) | 38 (29.0%) | |
(Missing) | 1 | 1 | 2 | |
IPI Risk (3 Groups) | 0.004c | |||
Low | 12 (21.8%) | 9 (11.7%) | 21 (15.9%) | |
Intermediate | 21 (38.2%) | 52 (67.5%) | 73 (55.3%) | |
High | 22 (40.0%) | 16 (20.8%) | 38 (28.8%) | |
(Missing) | 1 | 0 | 1 | |
COO IHC (Hans classification) | 0.999b | |||
GCB subtype | 45 (80.4%) | 62 (80.5%) | 107 (80.4%) | |
Non-GCB subtype | 5 (8.9%) | 8 (10.3%) | 13 (9.8%) | |
Not evaluable | 6 (13.3%) | 7 (9.1%) | 13 (9.8%) | |
Rearrangement | 0.0832 | |||
Single hit | 20 (35.7%) | 18 (23.4%) | 38 (28.6%) | |
Double/triple hit | 26 (46.4%) | 51 (66.2%) | 77 (57.9%) | |
Missing BCL2/BCL6 | 10 (17.9%) | 8 (10.4%) | 18 (13.5%) | |
Days before start treatment | 0.317a | |||
Median | 15.0 | 19.0 | 17.0 | |
IQR | 10.8–23.8 | 11.0–26.0 | 11.0–26.0 | |
Range | 5.0–84.0 | 0.0–69.0 | 0.0–84.0 | |
Response | 0.556c | |||
Complete remission | 37 (69.8%) | 62 (80.5%) | 99 (76.2%) | |
Partial remission | 11 (20.8%) | 11 (14.3%) | 22 (16.9%) | |
Stable disease | 1 (1.9%) | 1 (1.3%) | 2 (1.5%) | |
Progressive disease | 4 (7.5%) | 3 (3.9%) | 7 (5.4%) | |
(Missing) | 3 | 0 | 3 | |
Response (grouped) | 0.209b | |||
Complete remission | 37 (69.8%) | 62 (80.5%) | 99 (76.2%) | |
No complete remission | 16 (30.2%) | 15 (19.5%) | 31 (23.8%) | |
(Missing) | 3 | 0 | 3 |
